Is There a Stigma Attached to Antibodies?

2min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

There's been some talk about a potentially kind of information campaign to make sure that physicians realize where the state of he data is when it comes to timonical anobodies. Former president trump also really pushed a hydroxy chloriquin. Whether or not most physicians would, i don't know if it hert or helped. I think it probably depends on what part of the country you were living in and what part of the world you are living in.

In the early days of the pandemic, researchers raced to identify the most potent antibodies produced by the immune system in response to SAR-COV-2 infection and produce them in bulk. The resulting ‘monoclonal antibodies’ have since been tested in a variety of settings as treatments for COVID-19.

But despite promising clinical trial results and several therapies having already been approved, antibody therapies have not yet played a large role in the fight against COVID-19. In this episode of Coronapod, we ask why.

News: COVID antibody treatments show promise for preventing severe disease

News: Antibody therapies could be a bridge to a coronavirus vaccine — but will the world benefit?

Subscribe to Nature Briefing, an unmissable daily round-up of science news, opinion and analysis free in your inbox every weekday.

Hosted on Acast. See acast.com/privacy for more information.